BioNTech SE Sponsored ADR (NASDAQ:BNTX – Get Free Report) CEO Ugur Sahin sold 30,000 shares of the company’s stock in a transaction on Friday, September 18th. The stock was sold at an average price of $96.22, for a total value of $2,886,600.00. Following the sale, the chief executive officer owned 489,209 shares of the company’s stock, valued at $47,071,689.98. This trade represents a 5.78% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ugur Sahin also recently made the following trade(s):
- On Thursday, September 17th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $98.60, for a total value of $3,352,400.00.
- On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The shares were sold at an average price of $96.09, for a total value of $1,441,350.00.
- On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $96.49, for a total transaction of $3,280,660.00.
- On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The stock was sold at an average price of $99.45, for a total transaction of $4,077,450.00.
- On Friday, September 11th, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $96.93, for a total transaction of $4,361,850.00.
- On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The shares were sold at an average price of $96.31, for a total transaction of $1,974,355.00.
- On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The shares were sold at an average price of $97.78, for a total transaction of $3,520,080.00.
- On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The shares were sold at an average price of $99.20, for a total transaction of $3,670,400.00.
- On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The shares were sold at an average price of $103.52, for a total transaction of $3,260,880.00.
- On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $102.85, for a total transaction of $4,628,250.00.
BioNTech Trading Down 2.6%
Shares of BNTX stock opened at $96.06 on Friday. BioNTech SE Sponsored ADR has a 52-week low of $79.52 and a 52-week high of $124.00. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.80 and a current ratio of 7.85. The company has a 50-day simple moving average of $97.38 and a two-hundred day simple moving average of $94.93. The company has a market capitalization of $24.29 billion, a price-to-earnings ratio of -12.27 and a beta of 1.29.
Wall Street Analyst Weigh In
BNTX has been the subject of a number of research analyst reports. Morgan Stanley dropped their price target on BioNTech from $126.00 to $119.00 and set an “overweight” rating on the stock in a report on Wednesday, July 8th. Canaccord Genuity Group reduced their price objective on BioNTech from $142.00 to $136.00 and set a “buy” rating for the company in a research note on Monday, August 31st. Jefferies Financial Group restated a “buy” rating on shares of BioNTech in a research note on Monday, June 1st. UBS Group reaffirmed a “buy” rating on shares of BioNTech in a research report on Wednesday. Finally, BMO Capital Markets cut BioNTech from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $128.00 to $105.00 in a research note on Tuesday, September 8th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $126.00.
Read Our Latest Stock Analysis on BNTX
Institutional Trading of BioNTech
Several hedge funds have recently made changes to their positions in the company. Engineers Gate Manager LP lifted its position in shares of BioNTech by 17.3% during the 2nd quarter. Engineers Gate Manager LP now owns 12,433 shares of the company’s stock valued at $1,157,000 after buying an additional 1,833 shares during the last quarter. Integrated Wealth Concepts LLC purchased a new stake in BioNTech in the 2nd quarter worth about $39,000. Nykredit A S purchased a new stake in BioNTech in the 2nd quarter worth about $293,000. B. Metzler seel. Sohn & Co. AG raised its stake in BioNTech by 66.7% in the 2nd quarter. B. Metzler seel. Sohn & Co. AG now owns 10,967 shares of the company’s stock valued at $1,020,000 after acquiring an additional 4,390 shares during the period. Finally, Headlands Technologies LLC bought a new stake in BioNTech in the 2nd quarter valued at about $2,520,000. 15.52% of the stock is currently owned by institutional investors.
BioNTech Company Profile
BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.
The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.
BioNTech was founded in 2008 and is headquartered in Mainz, Germany.
Featured Articles
- Five stocks we like better than BioNTech
- J.B. Hunt’s Stock Plunges After Market Misprices Profit Warning
- 2 Stocks Breaking Out Post-FOMC With One Thing in Common
- Lennar’s Q3 Miss Hides a Stronger Operating Story Beneath the Housing Slump
- These 3 Stocks Are Drawing Insider Buyers for Very Different Reasons
Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.
